SM

Seelam Manojkumarreddy

Active Director Whole-Time Director DIN 06991382
DIN 06991382 First appointment Mar 2019 Primary industry General Business
Unlock full profile Investments · shareholding · contact details
Current companies 4 active board seats
Past companies 1 historical roles
Total affiliations 5 Since Mar 2019
Shareholding value •••• Premium profile

About Seelam Manojkumarreddy

Data last updated:

Seelam Manojkumarreddy has 7 years in corporate governance. Holds Whole-Time Director and Additional Director roles. Currently with 4 companies, including Concord Drugs Limited and Cortex Laboratories Private Limited. Formerly with 1 company, such as Continental Pellets Pharma Private Limited. Engaged in General Business. Contributes to corporate operations. The 4 current companies with reported revenue have a combined latest revenue of ₹82.00 Cr; the largest is Concord Drugs Limited at ₹45.26 Cr (FY 2025).

DIN 06991382
Primary Designation Whole-Time Director
First Appointment 16 Mar 2019
Oldest Company Age 31 yrs
Largest company Concord Drugs Limited · ₹45.26 Cr (FY 2025)
Combined revenue ₹82.00 Cr across 4 companies

Current companies

CompanyDesignationAppointmentFoundedRevenueStatus
Concord Drugs Limited L24230TG1995PLC020093
Whole-Time Director13 Aug 20211995₹45.26 Cr (FY 2025)Active
Cortex Laboratories Private Limited U24230TG1995PTC020588
Additional Director03 Feb 20201995₹16.61 Cr (FY 2025)Active
Proton Remedies Private Limited U24232TG2008PTC061073
Director02 Nov 20222008₹10.29 Cr (FY 2025)Active
Seelam Laboratories Private Limited U24232TG2010PTC068611
Director16 Mar 20192010₹9.84 Cr (FY 2024)Active

Previous companies

CompanyDesignationAppointmentFoundedRevenueStatus
Director20 Feb 20202020₹16 Lakh (FY 2025)Active

Explore Director's current and past company associations Uncover their professional journey today!

Directorship timeline

Open interactive timeline →
Concord Drugs Limited
Cortex Laboratories Private Limited
Proton Remedies Private Limited
Seelam Laboratories Private Limited
Premium access

Shareholding and investment profile for Seelam Manojkumarreddy

Company-level share counts, filed values, and quarterly changes require authenticated premium access.

  • Company-level holdings
  • Filed share counts
  • Reported values
  • Quarterly changes
Unlock shareholding

Verified entity values are shown only after access is granted.

Frequently Asked Questions about Seelam Manojkumarreddy

Seelam Manojkumarreddy has 7 years in corporate governance. Holds Whole-Time Director and Additional Director roles. Currently with 4 companies, including Concord Drugs Limited and Cortex Laboratories Private Limited. Formerly with 1 company, such as Continental Pellets Pharma Private Limited. Engaged in General Business. Contributes to corporate operations. The 4 current companies with reported revenue have a combined latest revenue of ₹82.00 Cr; the largest is Concord Drugs Limited at ₹45.26 Cr (FY 2025).

Seelam Manojkumarreddy is associated with 4 companies as Whole-Time Director and Additional Director, including Concord Drugs Limited (₹45.26 Cr), Cortex Laboratories Private Limited (₹16.61 Cr), Proton Remedies Private Limited (₹10.29 Cr).

Seelam Manojkumarreddy has expertise in General Business.

Seelam Manojkumarreddy has 7 years in corporate governance.

By reported revenue, the largest current company of Seelam Manojkumarreddy is Concord Drugs Limited, with revenue of ₹45.26 Cr (FY 2025).

The 4 current companies of Seelam Manojkumarreddy that report revenue have a combined latest revenue of ₹82.00 Cr.

Seelam Manojkumarreddy currently holds positions at 4 companies: Concord Drugs Limited (₹45.26 Cr), Cortex Laboratories Private Limited (₹16.61 Cr), Proton Remedies Private Limited (₹10.29 Cr), Seelam Laboratories Private Limited (₹9.84 Cr).

Explore millions of companies — effortlessly

Access structured, verified intelligence on 7M+ companies across industries, sectors, and global markets. From early-stage startups to large enterprises, discover ownership, leadership, funding, financials, acquisitions, and market signals — all in one powerful platform.

Free account with essential features Instant access to company reports Enterprise solutions available